Calquence capsules pass Real-World safety check in CLL patients
NCT ID NCT05665374
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at the safety of Calquence (acalabrutinib) capsules in 67 people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Researchers tracked side effects like infections and bone marrow problems during everyday use. The goal was to understand how safe the drug is outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Calquence (acalabrutinib) capsules 100 mg
What this could lead to
If successful, this study could confirm that Calquence is safe and manageable for people with untreated CLL in everyday medical practice.
What could go wrong
This is a small, completed safety study, not a large trial testing how well the drug works. Side effects like infections or bone marrow problems may still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aichi, Japan
-
Research Site
Chiba, Japan
-
Research Site
Fukuoka, Japan
-
Research Site
Hyōgo, Japan
-
Research Site
Kanagawa, Japan
-
Research Site
Kyoto, Japan
-
Research Site
Miyazaki, Japan
-
Research Site
Nagano, Japan
-
Research Site
Nara, Japan
-
Research Site
Okayama, Japan
-
Research Site
Osaka, Japan
-
Research Site
Saitama, Japan
-
Research Site
Shizuoka, Japan
-
Research Site
Tokyo, Japan
-
Research Site
Yamanashi, Japan